Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Post-hoc analysis of SYNERGY-NASH trial reveals key insights on #tirzepatide in #MASH patients MASH resolution linked to greater weight loss (-16% vs -7%) Fibrosis improvement associated with better glycemic control Liver fat normalization was key mediator of both outcomes Weight reduction + metabolic improvements = disease modification potential in MASH Scott Isaacs, MD, FACP, FACEs Post Post-hoc analysis of SYNERGY-NASH trial reveals key insights on #tirzepatide in #MASH patients MASH resolution linked to greater weight loss (-16% vs -7%) Fibrosis improvement associated with better glycemic control Liver fat normalization was key mediator of both outcomes Weight reduction + metabolic improvements = disease modification potential in MASH To view or add a comment, sign in More Relevant Posts Post-hoc analysis of SYNERGY-NASH trial showing how tirzepatide-driven weight loss and metabolic improvements are linked to MASH resolution and fibrosis improvement
KYNA then, is not only implicated in the resolution of inflammation via its anti-inflammatory effects, but also in the establishment of an immunosuppressive environment through regulation of immune cell functions [19]
These advancements aim to enhance patient compliance and convenience, potentially leading to better health outcomes and increased market penetration
Abruptly discontinuing the use of the medication may lead to weight gain, requiring continuous medical monitoring
Supporting fat transport, it helps you access energy stores more efficiently, which can be especially useful when youre in a calorie deficit or pushing hard in the gym
your appetite dials down, your stomach empties more slowly, and your blood sugar stabilizes
